Pipeline

June 24, 2019
Company Drug/Device Medical Condition Status
Cellular Biomedicine Group Inc. anti-CD20 CAR-T diffuse large B-cell lymphoma (DLBCL) Phase I trial initiated enrolling 12 subjects in China
Boehringer Ingelheim
OSE Immunotherapeutics SA		 SIRPα antagonist monoclonal antibody BI 765063 (formerly OSE-172) advanced solid tumors Phase I trial initiated
Rocket Pharmaceuticals, Inc. RP-A501 Danon disease Phase I trial initiated enrolling 12-24 pediatric and young adult male subjects
BioNTech SE
Genmab A/S		 DuoBody-PD-L1x4-1BB metastatic or unresectable malignant solid tumors Phase I/IIa trial initiated
Reistone Biopharma Company SHR0302 Ulcerative Colitis Phase II trial initiated
Reistone Biopharma Company SHR0302 Crohn's disease Phase II trial initiated
Zydus Cadila Saroglitazar Magnesium Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic SteatoHepatitis (NASH) Phase II trial initiated enrolling 104 subjects at 20 sites across the U.S.
InflaRx N.V. IFX-1 Pyoderma Gangraenosum (PG) Phase IIa trial initiated enrolling 12 subjects with moderate to severe PG at three sites in Canada
Corvidia Therapeutics Inc. Ziltivekimab (previously known as COR-001) advanced chronic kidney disease (CKD) Phase IIb trial initiated enrolling 240 subjects at 50 sites across the U.S.
Arena Pharmaceuticals, Inc. etrasimod 2 mg ulcerative colitis (UC) Phase III trial initiated enrolling subjects with moderately to severely active UC
OxThera AB Oxabact Primary Hyperoxaluria Phase III trial initiated enrolling 22 subjects at 10 sites across Europe and the U.S.
Torque TRQ-1501 relapsed or refractory solid tumors and lymphomas that express any of five tumor-associated antigens (PRAME, WT-1, SSX2, Survivin and NY-ESO-1) Fast Track designation granted by the FDA
Bio-Techne ExoDx Prostate IntelliScore (EPI) test prostate cancer Breakthrough Device designation granted by the FDA
Camurus CAM2029 acromegaly IND approval granted by the FDA
Triumvira Immunologics, Inc. TAC01-CD19 CD19-postive B-cell malignancies IND approval granted by the FDA
Amgen
Allergan plc		 KAJINTI (trastuzumab-anns) HER2-overexpressing adjuvant and metastatic breast cancer Approval granted by the FDA
Amgen
Allergan plc		 KAJINTI (trastuzumab-anns) HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma Approval granted by the FDA
Novo Nordisk Victoza (liraglutide) Type 2 diabetes in children and adolescents aged 10-17 years Approval granted by the FDA
Kowa Pharmaceuticals America, Inc. LIVALO (pitavastatin) heterozygous familial hypercholesterolemia (HeFH) in subjects eight years and older Approval granted by the FDA

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here